DEA advisory: fentanyl mixtures are outpacing naloxone

The DEA issued a public safety advisory on May 12, 2026 warning that the illicit drug supply is being cut with synthetic substances that limit the effectiveness of naloxone — the overdose-reversal medication that has, for the better part of a decade, been the single most consequential harm-reduction tool in the United States. The named adulterants are familiar to anyone following the supply chain: xylazine, medetomidine, nitazenes, and the relative newcomer cychlorphine.

What’s in the supply

Cychlorphine — N-propionitrile chlorphine — was flagged by the Center for Forensic Science Research and Education in a January 2026 alert as a rising cause of fatal overdoses; in vitro pharmacology suggests it is roughly 10 times as potent as fentanyl. After China placed nitazene analogues under generic control in July 2025, nitazene positivity in fatal cases declined while cychlorphine positivity rose — a textbook supply-substitution pattern. Medetomidine, an alpha-2 agonist 100–200 times more potent than xylazine, is now routinely identified in Philadelphia, Pittsburgh, and Chicago supply samples; medetomidine reports rose from 12 in 2021 to 2,276 in 2024.

What this means for naloxone use

Naloxone still works on the opioid in the mixture. It does not reverse medetomidine, xylazine, or the non-opioid sedation profile any of the alpha-2 agonists produce — meaning patients may remain sedated, with low heart rates and respiratory complications, even after naloxone administration. The DEA’s operational guidance is unchanged in its first instruction and amended in its second: give naloxone, give multiple doses, call 911, and do not assume someone is “fine” after they respond. Drug-checking programs in several states are now distributing point-of-care medetomidine test strips alongside fentanyl test strips; federal funding for those strips, however, was restricted by SAMHSA’s April 24 guidance letter.

Why this matters for people in recovery

If you carry naloxone — and you should, even if you don’t use drugs — the new advisory is not a reason to stop. It is a reason to learn the second-dose habit, the rescue-breath habit, and the call-911 habit. Rize’s family harm-reduction guide walks through what to do when someone is unresponsive, in plain language.

In an active overdose, call 911 immediately. For non-emergency support: SAMHSA 1-800-662-HELP (4357).

— The Rize Recovery Newsroom